证券代码：603883 证券简称：老百姓 公告编号：2025-066 老百姓大药房连锁股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 28 日 (二)股东大会召开的地点：湖南省长沙市开福区青竹湖路 808 号老百姓 15 楼会 议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 593 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 371,553,471 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 48.9601 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票和网络投票相结合的方式召开，老百姓大药房连锁股份有 限公司（以下简称"公司"）董事会召集本次会 ...

湖南启元律师事务所 关于老百姓大药房连锁股份有限公司 2025年第一次临时股东大会的 法律意见书 二零二五年十一月二十八日 湖南启元律师事务所（以下简称"本所"）接受老百姓大药房连锁股份有限 公司（以下简称"公司"）的委托，指派律师出席了公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席 会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并 发表本法律意见。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《老百姓 大药房连锁股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 为出具本法律意见书，本所声明如下： （一）本所出具本法律意见书是基于公司已承诺所有提供给本所的文件的正 本以及经本所查验与正本保持一致的副本均为真实、完整、可靠，无隐瞒、虚假 或重大遗漏之处。 （二）本所遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对本法 律意见书出具日以前已经发生 ...

Core Viewpoint - The Chinese government is implementing policies to enhance the adaptability of consumer goods supply and demand, aiming to promote consumption by aligning production with consumer preferences [1] Group 1 - The government encourages enterprises to understand and produce what consumers want, ensuring that products meet market demand and quality standards [1] - The initiative aims to provide consumers with satisfactory products and services, which in turn benefits businesses by ensuring their products are well-suited for the market [1]

Core Viewpoint - The Chinese government is implementing policies to enhance the adaptability of supply and demand in consumer goods, aiming to better align production with consumer preferences and improve service quality [2]. Group 1: Policy Measures - The government encourages enterprises to understand and produce what consumers want, ensuring that products are suitable and of high quality [2]. - The focus is on guiding companies to innovate and meet the demands of consumers, which will ultimately benefit both consumers and businesses [2].

Core Viewpoint - The demand for respiratory disease-related medications and protective supplies has significantly increased as respiratory diseases like influenza and mycoplasma pneumonia enter a high incidence season in China [2][3]. Group 1: Market Demand and Supply - The China Disease Prevention and Control Center has reported an upward trend in influenza cases, with sentinel hospitals in southern provinces reporting a percentage of influenza-like cases at 6.7% and northern provinces at 7.0% during the 46th week of 2025, indicating an earlier onset of the flu season compared to previous years [2]. - The company, Lao Bai Xi Da Yao Fang, has leveraged its nationwide supply chain and store network to ensure stable supply and price stability for four categories of medications, including antiviral drugs, antipyretics, cough suppressants, and antibiotics, as well as protective supplies like masks [2][3]. Group 2: Sales Performance - Sales of antiviral medications such as Oseltamivir and Mabalaoshuai (Sufuda), as well as antibiotics like Amoxicillin and Azithromycin, have seen significant growth recently, particularly in November, with a notable increase in sales of flu medications [3]. - The company has implemented a supply guarantee plan in anticipation of seasonal demand fluctuations, which includes early forecasting, centralized procurement, and increased stock levels to ensure market supply stability [3]. Group 3: Health Recommendations - The China Disease Prevention and Control Center has noted an increase in reported influenza outbreaks, particularly among children aged 5 to 14, and has recommended health monitoring in key institutions such as schools and nursing homes [4]. - The company emphasizes the importance of following medical advice for flu prevention and treatment, including vaccination, medication adherence, mask-wearing, hand hygiene, and environmental disinfection [4].

Core Viewpoint - The Chinese government is implementing policies to enhance the adaptability of consumer goods supply and demand, aiming to stimulate consumption and promote economic circulation [1][3]. Group 1: Policy Goals - The "Implementation Plan" sets two main development goals: to establish three trillion-level consumption sectors and ten hundred-billion-level consumption hotspots by 2027, and to create a high-quality development pattern of positive interaction between supply and consumption by 2030 [3][4]. - The plan emphasizes the importance of aligning supply with consumer demand to maximize consumption potential and facilitate economic growth [3]. Group 2: Key Measures - The plan outlines five key measures to address supply-demand mismatches: 1. Expand new increments by accelerating the application of new technologies and innovative models, promoting flexible production and user participation in design [3][4]. 2. Deepen existing stock by enhancing the supply of specialized and new products, focusing on areas like green, health, and rural consumption [4]. 3. Segment the market to precisely match the needs of different demographic groups, including initiatives for children's and elderly products [4][5]. 4. Empower new consumption scenarios and business formats by fostering platforms for product launches and developing new retail formats [5].

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券代码：603883 证券简称：老百姓 公告编号：2025-065 老百姓大药房连锁股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 12 月 2 日(星期二)上午 10:00-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 11 月 25 日(星期二)至 12 月 1 日(星期一)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@lbxdrugs.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 老百姓大药房连锁股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日披露公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成 ...

Group 1: Company Overview - Amer Sports - Amer Sports reported Q3 2025 revenue of $1.76 billion, exceeding guidance with a year-on-year growth of 30%, surpassing the high end of the guidance range of 20% [3][41] - The adjusted gross margin increased by 2.4 percentage points to 57.9%, while the adjusted operating margin rose by 1.3 percentage points to 15.7%, also exceeding guidance [3][41] - The net profit attributable to shareholders surged by 156% year-on-year to $140 million [3][41] Group 2: Segment Performance - The functional apparel segment saw a 31% year-on-year revenue increase, driven by strong performance in the women's business and footwear, with direct-to-consumer (DTC) sales up 46% [3][42] - The outdoor apparel segment experienced a 36% year-on-year revenue growth, primarily due to strong sales of Salomon footwear and apparel, with DTC sales increasing by 67% [4][42] - The ball sports segment reported a 16% year-on-year revenue increase, with significant growth potential through partnerships with leading distributors [4][43] Group 3: Strategic Outlook - The company maintains a positive long-term growth outlook, projecting a compound annual growth rate (CAGR) of low to mid-double digits for revenue from 2025 to 2030, with annual operating margin improvements [5][43] - The strategic plan includes continued investment in product development and marketing, particularly in expanding store presence in North America and Europe [5][43] - The company anticipates a significant increase in revenue from the recovery of its South Korean distribution business, expected to add approximately $25 million in Q4 2025 [3][42] Group 4: Industry Context - Retail and Pharmaceuticals - The retail sector, particularly in the pharmaceutical industry, is experiencing pressure, with the company reporting a 1% decline in revenue for the first three quarters of 2025 [6][8] - The company is focusing on store expansion in lower-tier markets, with a total of 15,492 stores as of Q3 2025, including 9,741 direct-operated stores [9][8] - The pharmaceutical retail business reported a revenue of $13.144 billion, a slight decline of 1.27% year-on-year, with a gross margin of 36.71% [8][9]

Core Viewpoint - The company, Lao Bai Xing, has experienced a decline in stock price and financial performance, with significant changes in shareholder structure and trading activity [1][2]. Group 1: Stock Performance - On November 20, Lao Bai Xing's stock price fell by 1.51%, with a trading volume of 197 million yuan [1]. - The financing buy-in amount for the day was 17.15 million yuan, while the financing repayment was 16.26 million yuan, resulting in a net financing buy of 890,200 yuan [1]. - As of November 20, the total financing and securities lending balance was 516 million yuan, with the financing balance at 515 million yuan, accounting for 4.15% of the circulating market value, which is below the 40th percentile level over the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Lao Bai Xing reported a revenue of 16.07 billion yuan, a year-on-year decrease of 1.00%, and a net profit attributable to shareholders of 529 million yuan, down 16.11% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 2.175 billion yuan in dividends, with 1.097 billion yuan distributed over the past three years [2]. Group 3: Shareholder Structure - As of October 31, the number of shareholders for Lao Bai Xing increased to 63,700, up by 1.94%, while the average circulating shares per person decreased by 1.90% to 11,921 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.76 million shares, a decrease of 7.32 million shares from the previous period [2].